GLP-1 agonists for people living with HIV and obesity, is there a potential?

Zino, L; Tack, C J; Richel, O; Burger, D M

Zino, L; Tack, C J; Richel, O; Burger, D M.

Affiliation

Zino L; Radboud University Medical Center, Department of Pharmacy and Radboudumc Research Institute for Medical Innovation (RIMI), Nijmegen, The Netherlands.
Tack CJ; Radboud University Medical Center, Department of Internal Medicine and Radboudumc Research Institute for Medical Innovation (RIMI), Nijmegen, The Netherlands.
Richel O; Radboud University Medical Center, Department of Internal Medicine and Radboudumc Research Institute for Medical Innovation (RIMI), Nijmegen, The Netherlands.
Burger DM; Radboud University Medical Center, Department of Pharmacy and Radboudumc Research Institute for Medical Innovation (RIMI), Nijmegen, The Netherlands.

HIV Med ; 24(10): 1029-1034, 2023 10.

Article in En | MEDLINE | ID: mdl-37340561

Subject(s)

Diabetes Mellitus, Type 2; HIV Infections; Humans; Liraglutide/adverse effects; Hypoglycemic Agents/adverse effects; HIV Infections/drug therapy; Glucagon-Like Peptide 1/therapeutic use; Obesity/complications; Obesity/drug therapy; Weight Loss

Key words

GLP-1 agonist; HIV; liraglutide; obesity; semaglutide

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Infections / Diabetes Mellitus, Type 2 Type of study: Guideline / Risk_factors_studies Limits: Humans Language: En Journal: HIV Med Journal subject: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Year: 2023 Type: Article Affiliation country: Netherlands

Fulltext

XML

PubMed Links

Search on Google